Neoflubin 25 mg/ml Konzentrat zur Herstellung einer Injektions- oder Infusionslösung
Sponsors
Celgene Corp., F. Hoffmann-La Roche AG
Conditions
Chronic Lymphocytic Leukemia (CLL)Newly Diagnosed Multiple Myeloma with Suboptimal Response After Autologous Stem Cell Transplantation
Phase 3
A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Active, not recruitingCTIS2022-501346-30-00
Start: 2023-09-25Target: 332Updated: 2025-12-09
A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine and Rituximab (BR) in FIT Patients with previously untreated Chronic Lymphocytic Leukemia (CLL) without DEL(17P) or TP53 Mutation
CompletedCTIS2023-504036-17-00
Start: 2020-05-07End: 2025-03-18Target: 121Updated: 2025-04-17